Clin2
NCT07315633Possibly a fitRecruiting

Personalized TARE treatment planning for liver cancer

Hepatocellular Carcinoma (HCC)Liver Cancer, AdultLiver Cancer

Part of Cancer, Digestive system clinical trials.

This trial is testing a new computer tool that uses your own scans to plan TARE treatment for liver cancer. The goal is to make the treatment more personalized and effective.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
80 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have been diagnosed with liver cancer (HCC).
  • You are planning to get or have already received a treatment called TARE (transarterial radioembolization).
  • You had imaging scans (like CT, MRI, or PET) of your liver's blood vessels before TARE, which can be used to create a 3D model of your liver's arteries.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07183566Not yet recruiting
CT volume measurement for liver cancer treatment planning

This trial uses CT scans to measure the volume of liver tumors in people with hepatocellular carcinoma (HCC) who cannot have surgery. The goal is to see if this measurement helps guide treatment with TACE, a procedure that blocks blood flow to the tumor.

NCT07293468Recruiting· Phase 2/Phase 3
Comparing two treatments for advanced liver cancer

This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).

Hong Kong
NCT07356531Recruiting
Thermosensitive Embolic Agent for Liver Cancer TACE

This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.

Hefei, Anhui
NCT07414433Not yet recruiting
Blood test study for liver cancer patients getting TACE treatment

This study looks at special blood markers in people with liver cancer (hepatocellular carcinoma) who are about to have a procedure called TACE. The goal is to see if these markers can help predict how well the treatment works. You may be able to join if you are getting TACE as part of your standard care.

Belgrade
NCT07378709Recruiting
Blood markers for TACE-treated liver cancer

This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.

Belgrade
NCT07669727Not yet recruiting
Study on personalized radiation for untreated liver tumors

This study checks how well a custom radiation treatment plan works for people with a single liver tumor (HCC) that hasn't been treated before. TheraSphere uses tiny beads with radiation to target the tumor while sparing healthy liver.

Hear when a new Hepatocellular Carcinoma (HCC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.